Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today...

Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly...

Receives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin® LAR Depot (Octreotide Acetate for Injectable Suspension) U.S. FDA Accepts New Drug Application for...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13,...

Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Compete Restrictions PITTSBURGH, Dec. 6, 2025...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in December 2025. The Company will participate in...

Viatris Inc. (Nasdaq: VTRS) today announced that it has been recognized as one of the Fortune World's Best Workplaces™ in 2025. The list of 25 global leaders was selected from organizations that...

Delivers Total Revenues in Line With Expectations, Reflecting Strong Execution of its Global Business Makes Late-Stage Pipeline Progress Including NDA Submission for Low-Dose Estrogen Weekly Patch...